vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Marathon Bancorp, Inc. (MBBC). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $2.2M, roughly 1.1× Marathon Bancorp, Inc.). Marathon Bancorp, Inc. runs the higher net margin — 22.3% vs -265.2%, a 287.5% gap on every dollar of revenue. Over the past eight quarters, Marathon Bancorp, Inc.'s revenue compounded faster (20.3% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Marathon Bancorp, Inc. is a Maryland-based financial holding company that primarily operates through its community bank subsidiary. It offers a full range of retail and commercial banking products including deposit accounts, consumer loans, commercial mortgages, and small business financing, serving individual and small-to-medium enterprise customers across local markets in Maryland.
BOLT vs MBBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $2.2M |
| Net Profit | $-6.6M | $501.4K |
| Gross Margin | — | — |
| Operating Margin | -283.4% | 26.2% |
| Net Margin | -265.2% | 22.3% |
| Revenue YoY | — | 41.7% |
| Net Profit YoY | 58.4% | 880.7% |
| EPS (diluted) | $-9.38 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $2.2M | ||
| Q3 25 | $2.2M | $2.1M | ||
| Q2 25 | $1.8M | $1.9M | ||
| Q1 25 | $1.2M | $1.7M | ||
| Q4 24 | $0 | $1.6M | ||
| Q3 24 | $1.1M | $1.6M | ||
| Q2 24 | $1.3M | $1.6M | ||
| Q1 24 | $5.3M | $1.6M |
| Q4 25 | $-6.6M | $501.4K | ||
| Q3 25 | $-7.1M | $444.3K | ||
| Q2 25 | $-8.6M | $-332.0K | ||
| Q1 25 | $-11.0M | $148.4K | ||
| Q4 24 | $-15.9M | $51.1K | ||
| Q3 24 | $-15.2M | $174.9K | ||
| Q2 24 | $-21.2M | $85.8K | ||
| Q1 24 | $-10.8M | $-631.1K |
| Q4 25 | -283.4% | 26.2% | ||
| Q3 25 | -355.1% | 25.5% | ||
| Q2 25 | -510.5% | -25.7% | ||
| Q1 25 | -991.4% | 11.6% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -1441.1% | 13.4% | ||
| Q2 24 | -1772.3% | 4.1% | ||
| Q1 24 | -324.1% | -53.7% |
| Q4 25 | -265.2% | 22.3% | ||
| Q3 25 | -329.4% | 20.7% | ||
| Q2 25 | -474.6% | -18.9% | ||
| Q1 25 | -903.4% | 8.9% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | -1330.1% | 10.8% | ||
| Q2 24 | -1662.4% | 6.2% | ||
| Q1 24 | -205.0% | -40.7% |
| Q4 25 | $-9.38 | $0.19 | ||
| Q3 25 | $-3.72 | $0.17 | ||
| Q2 25 | $-4.46 | $-0.13 | ||
| Q1 25 | $-0.29 | $0.07 | ||
| Q4 24 | $-13.73 | $0.02 | ||
| Q3 24 | $-7.93 | $0.06 | ||
| Q2 24 | $-11.12 | $0.07 | ||
| Q1 24 | $-0.28 | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $46.9M |
| Total Assets | $56.7M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | — | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | — |
| Q4 25 | $26.5M | $46.9M | ||
| Q3 25 | $32.1M | $46.3M | ||
| Q2 25 | $38.8M | $45.7M | ||
| Q1 25 | $46.8M | $32.0M | ||
| Q4 24 | $57.2M | $31.7M | ||
| Q3 24 | $72.0M | $31.6M | ||
| Q2 24 | $85.9M | $31.3M | ||
| Q1 24 | $104.2M | $31.4M |
| Q4 25 | $56.7M | $248.0M | ||
| Q3 25 | $65.1M | $246.0M | ||
| Q2 25 | $75.5M | $238.8M | ||
| Q1 25 | $85.9M | $236.8M | ||
| Q4 24 | $99.6M | $217.9M | ||
| Q3 24 | $109.3M | $216.5M | ||
| Q2 24 | $124.2M | $219.3M | ||
| Q1 24 | $142.9M | $225.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $1.4M |
| Free Cash FlowOCF − Capex | — | $1.4M |
| FCF MarginFCF / Revenue | — | 62.3% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 2.82× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $1.4M | ||
| Q3 25 | $-9.7M | $464.0K | ||
| Q2 25 | $-9.6M | $1.4M | ||
| Q1 25 | $-13.4M | $849.0K | ||
| Q4 24 | $-14.4M | $113.6K | ||
| Q3 24 | $-14.0M | $945.2K | ||
| Q2 24 | $-16.1M | $416.6K | ||
| Q1 24 | $-16.8M | $-802.1K |
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $456.6K | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $773.2K | ||
| Q4 24 | — | $105.0K | ||
| Q3 24 | $-14.0M | $921.6K | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | — | 62.3% | ||
| Q3 25 | — | 21.3% | ||
| Q2 25 | — | 66.0% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | -1227.6% | 57.1% | ||
| Q2 24 | — | -118.5% | ||
| Q1 24 | — | -67.9% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 3.6% | 1.5% | ||
| Q2 24 | 0.0% | 145.2% | ||
| Q1 24 | 0.0% | 16.2% |
| Q4 25 | — | 2.82× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.72× | ||
| Q4 24 | — | 2.22× | ||
| Q3 24 | — | 5.40× | ||
| Q2 24 | — | 4.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
